Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioEBIT MarginEBITDA MarginEBT MarginEnterprise ValueFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on SalesTimes Interest Earned

BioLineRx (BLRX) Return on Capital Employed (2023 - 2025)

Historic Return on Capital Employed for BioLineRx (BLRX) over the last 3 years, with Q3 2025 value amounting to 0.41%.

  • BioLineRx's Return on Capital Employed rose 6200.0% to 0.41% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.41%, marking a year-over-year increase of 6200.0%. This contributed to the annual value of 0.57% for FY2024, which is N/A changed from last year.
  • According to the latest figures from Q3 2025, BioLineRx's Return on Capital Employed is 0.41%, which was up 6200.0% from 0.52% recorded in Q2 2025.
  • BioLineRx's Return on Capital Employed's 5-year high stood at 0.41% during Q3 2025, with a 5-year trough of 3.18% in Q4 2023.
  • For the 3-year period, BioLineRx's Return on Capital Employed averaged around 1.21%, with its median value being 0.85% (2024).
  • As far as peak fluctuations go, BioLineRx's Return on Capital Employed soared by 25100bps in 2024, and later soared by 6200bps in 2025.
  • BioLineRx's Return on Capital Employed (Quarter) stood at 3.18% in 2023, then skyrocketed by 79bps to 0.67% in 2024, then soared by 39bps to 0.41% in 2025.
  • Its Return on Capital Employed was 0.41% in Q3 2025, compared to 0.52% in Q2 2025 and 0.66% in Q1 2025.